[HTML][HTML] Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials
Abstract Purpose Interleukin-6 (IL-6) levels discriminate between patients with mild and
severe COVID-19, making IL-6 inhibition an attractive therapeutic strategy. We conducted a …
severe COVID-19, making IL-6 inhibition an attractive therapeutic strategy. We conducted a …
[HTML][HTML] Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials
TAC Snow, N Saleem, G Ambler, E Nastouli… - Intensive Care …, 2021 - ncbi.nlm.nih.gov
Purpose Interleukin-6 (IL-6) levels discriminate between patients with mild and severe
COVID-19, making IL-6 inhibition an attractive therapeutic strategy. We conducted a …
COVID-19, making IL-6 inhibition an attractive therapeutic strategy. We conducted a …
Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials
STA Chandos, S Naveed, G Ambler… - Intensive Care …, 2021 - search.proquest.com
Purpose Interleukin-6 (IL-6) levels discriminate between patients with mild and severe
COVID-19, making IL-6 inhibition an attractive therapeutic strategy. We conducted a …
COVID-19, making IL-6 inhibition an attractive therapeutic strategy. We conducted a …
Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials.
TAC Snow, N Saleem, G Ambler, E Nastouli… - Intensive Care …, 2021 - europepmc.org
Purpose Interleukin-6 (IL-6) levels discriminate between patients with mild and severe
COVID-19, making IL-6 inhibition an attractive therapeutic strategy. We conducted a …
COVID-19, making IL-6 inhibition an attractive therapeutic strategy. We conducted a …
[PDF][PDF] Tocilizumab in COVID-19-A meta-analysis, trial sequential analysis, and meta-regression of randomized controlled trials
T Snow - core.ac.uk
Abstract Purpose: Interleukin-6 (IL-6) levels discriminate between patients with mild and
severe COVID-19, making IL-6 inhibition an attractive therapeutic strategy. We conducted a …
severe COVID-19, making IL-6 inhibition an attractive therapeutic strategy. We conducted a …
Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials.
TAC Snow, N Saleem, G Ambler, E Nastouli, M Singer… - 2021 - cabidigitallibrary.org
Abstract Purpose: Interleukin-6 (IL-6) levels discriminate between patients with mild and
severe COVID-19, making IL-6 inhibition an attractive therapeutic strategy. We conducted a …
severe COVID-19, making IL-6 inhibition an attractive therapeutic strategy. We conducted a …
Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials
TAC Snow, N Saleem, G Ambler… - Intensive care …, 2021 - pubmed.ncbi.nlm.nih.gov
Purpose Interleukin-6 (IL-6) levels discriminate between patients with mild and severe
COVID-19, making IL-6 inhibition an attractive therapeutic strategy. We conducted a …
COVID-19, making IL-6 inhibition an attractive therapeutic strategy. We conducted a …
Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials
TAC Snow, N Saleem, G Ambler… - Intensive Care …, 2021 - discovery.ucl.ac.uk
PURPOSE: Interleukin-6 (IL-6) levels discriminate between patients with mild and severe
COVID-19, making IL-6 inhibition an attractive therapeutic strategy. We conducted a …
COVID-19, making IL-6 inhibition an attractive therapeutic strategy. We conducted a …
Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials.
TAC Snow, N Saleem, G Ambler, E Nastouli… - Intensive Care …, 2021 - europepmc.org
Purpose Interleukin-6 (IL-6) levels discriminate between patients with mild and severe
COVID-19, making IL-6 inhibition an attractive therapeutic strategy. We conducted a …
COVID-19, making IL-6 inhibition an attractive therapeutic strategy. We conducted a …